SG11201702310QA - Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof - Google Patents

Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

Info

Publication number: SG11201702310QA
Authority: SG; Singapore
Prior art keywords: binding; specific monovalent; monovalent diabodies; diabodies; specific
Prior art date: 2014-09-26

Application number

SG11201702310QA

Inventor

Leslie S Johnson

Ezio Bonvini

Chia-Ying Kao Lam

Paul A Moore

Liqin Liu

Scott Koenig

Original Assignee

Macrogenics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-26

Filing date

2015-09-22

Publication date

2017-04-27

2015-09-22 Application filed by Macrogenics Inc filed Critical Macrogenics Inc

2017-04-27 Publication of SG11201702310QA publication Critical patent/SG11201702310QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Epoxy Compounds (AREA)
Polyesters Or Polycarbonates (AREA)
Furan Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

SG11201702310QA 2014-09-26 2015-09-22 Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof SG11201702310QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462055695P	2014-09-26	2014-09-26
PCT/US2015/051314 WO2016048938A1 (en)	2014-09-26	2015-09-22	Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

Publications (1)

Publication Number	Publication Date
SG11201702310QA true SG11201702310QA (en)	2017-04-27

Family

ID=55581876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201702310QA SG11201702310QA (en)	2014-09-26	2015-09-22	Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

Country Status (29)

Country	Link
US (3)	US10633443B2 (en)
EP (1)	EP3197917B1 (en)
JP (1)	JP6839075B2 (en)
KR (1)	KR20170063755A (en)
CN (1)	CN107484416A (en)
AP (1)	AP2017009823A0 (en)
AR (1)	AR101997A1 (en)
AU (1)	AU2015321546B2 (en)
CA (1)	CA2962603A1 (en)
CL (1)	CL2017000711A1 (en)
CO (1)	CO2017002793A2 (en)
CR (1)	CR20170109A (en)
CU (1)	CU20170041A7 (en)
DO (1)	DOP2017000083A (en)
EA (1)	EA201790719A1 (en)
ES (1)	ES2935062T3 (en)
IL (1)	IL251377B (en)
MA (1)	MA40573A (en)
MD (1)	MD20170040A2 (en)
MX (1)	MX375669B (en)
NI (1)	NI201700037A (en)
PE (1)	PE20170894A1 (en)
PH (1)	PH12017500544A1 (en)
SG (1)	SG11201702310QA (en)
TN (1)	TN2017000106A1 (en)
TW (1)	TWI706960B (en)
UY (1)	UY36316A (en)
WO (1)	WO2016048938A1 (en)
ZA (1)	ZA201701985B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
SG11201702310QA (en) *	2014-09-26	2017-04-27	Macrogenics Inc	Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
AU2015323860B2 (en)	2014-09-29	2021-05-27	Duke University	Bispecific molecules comprising an HIV-1 envelope targeting arm
AR106188A1 (en)	2015-10-01	2017-12-20	Hoffmann La Roche	ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
AR107781A1 (en)	2015-12-14	2018-06-06	Macrogenics Inc	BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME
SG11201907753TA (en)	2017-02-24	2019-09-27	Macrogenics Inc	Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201912774RA (en)	2017-06-20	2020-01-30	Teneobio Inc	Anti-bcma heavy chain-only antibodies
EP3684817A4 (en) *	2017-09-22	2021-06-09	Wuxi Biologics Ireland Limited.	NEW BISPECIFIC CD3 / CD19 POLYPEPTID COMPLEXES
MA50188A (en)	2017-09-22	2021-06-02	Wuxi Biologics Ireland Ltd	NEW BISPECIFIC POLYPEPTIDIC COMPLEXES
MA50670A (en) *	2017-09-29	2020-08-05	Janssen Biotech Inc	NEW FORMULATIONS TO STABILIZE LOW-DOSE ANTIBODY COMPOSITIONS
CN109706163A (en) *	2017-10-26	2019-05-03	深圳新诺微环生物科技有限公司	Bridging molecules and its application of minicircle dna expression connection people and animal target cells and effector cell
CN109957026A (en) *	2017-12-22	2019-07-02	成都恩沐生物科技有限公司	Covalent multi-specificity antibody
CA3089877A1 (en)	2018-02-15	2019-08-22	Macrogenics, Inc.	Variant cd3-binding domains and their use in combination therapies for the treatment of disease
WO2020018922A1 (en)	2018-07-20	2020-01-23	Teneobio, Inc.	Heavy chain antibodies binding to cd19
CN109402168A (en) *	2018-10-30	2019-03-01	深圳新诺微环生物科技有限公司	Bridging molecules and its application of minicircle dna expression connection HER2 positive cell and effector cell
WO2020088164A1 (en) *	2018-11-01	2020-05-07	山东新时代药业有限公司	Bispecific antibody and use thereof
WO2020052692A2 (en) *	2018-12-04	2020-03-19	Novartis Ag	Binding molecules against cd3 and uses thereof
JP2022525435A (en) *	2019-04-08	2022-05-13	メモリアルスローンケタリングキャンサーセンター	CD19 antibody and method of using it
KR20220010544A (en)	2019-05-21	2022-01-25	노파르티스 아게	CD19 binding molecules and uses thereof
CN112111012B (en) *	2019-06-20	2023-07-04	成都恩沐生物科技有限公司	Covalent Multispecific Antibodies
WO2022165171A1 (en)	2021-01-28	2022-08-04	Regeneron Pharmaceuticals, Inc.	Compositions and methods for treating cytokine release syndrome
CN113488112A (en) *	2021-06-10	2021-10-08	五邑大学	Covalent binding prediction method and device
EP4507790A1 (en)	2022-04-11	2025-02-19	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
US20240277844A1 (en)	2023-02-17	2024-08-22	Regeneron Pharmaceuticals, Inc.	Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0092918B1 (en)	1982-04-22	1988-10-19	Imperial Chemical Industries Plc	Continuous release formulations
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en)	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
DE3883899T3 (en)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	CHANGED ANTIBODIES.
AU6290090A (en)	1989-08-29	1991-04-08	University Of Southampton	Bi-or trispecific (fab)3 or (fab)4 conjugates
AU6430190A (en)	1989-10-10	1991-05-16	Pitman-Moore, Inc.	Sustained release composition for macromolecular proteins
EP0550436A1 (en)	1989-11-06	1993-07-14	Alkermes Controlled Therapeutics, Inc.	Protein microspheres and methods of using them
DE69232706T2 (en)	1991-05-01	2002-11-28	Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville	METHOD FOR TREATING INFECTIOUS RESPIRATORY DISEASES
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
AU669124B2 (en)	1991-09-18	1996-05-30	Kyowa Hakko Kirin Co., Ltd.	Process for producing humanized chimera antibody
AU2605592A (en)	1991-10-15	1993-04-22	Atrix Laboratories, Inc.	Polymeric compositions useful as controlled release implants
US5912015A (en)	1992-03-12	1999-06-15	Alkermes Controlled Therapeutics, Inc.	Modulated release from biocompatible polymers
GB9225453D0 (en)	1992-12-04	1993-01-27	Medical Res Council	Binding proteins
US5934272A (en)	1993-01-29	1999-08-10	Aradigm Corporation	Device and method of creating aerosolized mist of respiratory drug
CA2207961A1 (en)	1995-01-05	1996-07-11	Robert J. Levy	Surface-modified nanoparticles and method of making and using same
US6019968A (en)	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US5916597A (en)	1995-08-31	1999-06-29	Alkermes Controlled Therapeutics, Inc.	Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5736152A (en)	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
WO1997032572A2 (en)	1996-03-04	1997-09-12	The Penn State Research Foundation	Materials and methods for enhancing cellular internalization
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US5922845A (en)	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ATE287257T1 (en)	1997-01-16	2005-02-15	Massachusetts Inst Technology	PREPARATION OF PARTICLE-CONTAINING MEDICINAL PRODUCTS FOR INHALATION
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
SE512663C2 (en)	1997-10-23	2000-04-17	Biogram Ab	Active substance encapsulation process in a biodegradable polymer
ES2198922T3 (en)	1998-06-24	2004-02-01	Advanced Inhalation Research, Inc.	LARGE POROUS PARTICLES ISSUED BY AN INHALER.
WO2002002781A1 (en)	2000-06-30	2002-01-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Heterodimeric fusion proteins
US6992234B2 (en)	2000-11-06	2006-01-31	The Jackson Laboratory	FcRn-based therapeutics for the treatment of auto-immune disorders
ITRM20010408A1 (en)	2001-07-10	2003-01-10	Univ Napoli Federico Ii	CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR.
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
EP1293514B1 (en)	2001-09-14	2006-11-29	Affimed Therapeutics AG	Multimeric single chain tandem Fv-antibodies
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
CA2605024C (en)	2005-04-15	2018-05-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9284375B2 (en) *	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
SG153825A1 (en)	2005-12-16	2009-07-29	Ibc Pharmaceuticals Inc	Multivalent immunoglobulin-based bioactive assemblies
CA2654317A1 (en)	2006-06-12	2007-12-21	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
AT503889B1 (en)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	METHOD FOR MANIPULATING IMMUNE LOBULINS
ES2399075T3 (en)	2006-08-30	2013-03-25	Genentech, Inc.	Multispecific Antibodies
CN107226864A (en)	2007-06-21	2017-10-03	宏观基因有限公司	Covalent diabodies and application thereof
JP5727786B2 (en)	2007-10-19	2015-06-03	シアトルジェネティクス，インコーポレーテッド	CD19 binding substance and use thereof
EP2113255A1 (en)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Cytotoxic immunoglobulin
WO2010028795A1 (en)	2008-09-10	2010-03-18	F. Hoffmann-La Roche Ag	Multivalent antibodies
WO2010028797A1 (en)	2008-09-10	2010-03-18	F. Hoffmann-La Roche Ag	Multivalent antibodies
WO2010028796A1 (en)	2008-09-10	2010-03-18	F. Hoffmann-La Roche Ag	Trispecific hexavalent antibodies
SI2786762T1 (en)	2008-12-19	2019-07-31	Macrogenics, Inc.	Covalent diabodies and uses thereof
KR20130080871A (en)	2009-03-20	2013-07-15	제넨테크, 인크.	Bispecific anti-her antibodies
BRPI1007602A2 (en)	2009-05-27	2016-02-16	Hoffmann La Roche	"tri or tetraspecific antibody, method for preparing a trispecific or tetraspecific antibody, host cell, composition, pharmaceutical composition and method for treating a patient in need of therapy"
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
CA2787074A1 (en) *	2010-01-19	2011-07-28	Immunomedics, Inc.	Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r)
US20110206672A1 (en)	2010-02-25	2011-08-25	Melvyn Little	Antigen-Binding Molecule And Uses Thereof
CN102946906B (en)	2010-04-23	2015-07-15	弗·哈夫曼-拉罗切有限公司	Production of heteromultimeric proteins
SG187682A1 (en)	2010-08-02	2013-03-28	Macrogenics Inc	Covalent diabodies and uses thereof
EP2709655B1 (en)	2011-05-17	2018-11-14	Trion Research GmbH	Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
HUE044209T2 (en)	2011-05-21	2019-10-28	Macrogenics Inc	Cd3-binding molecules capable of binding to human and non-human cd3
EA201391753A1 (en) *	2011-05-21	2014-08-29	Макродженикс, Инк.	DOMAINS CONNECTING WITH DEIMMUNIZED SERUM AND THEIR APPLICATION TO INCREASE THE TIME OF HALF-DURATION
WO2012162583A1 (en)	2011-05-26	2012-11-29	Ibc Pharmaceuticals, Inc.	Design and construction of novel multivalent antibodies
WO2013003647A2 (en)	2011-06-28	2013-01-03	Sea Lane Biotechnologies, Llc	Multispecific stacked variable domain binding proteins
US20140155581A1 (en)	2011-07-06	2014-06-05	Medimmune, Llc	Methods For Making Multimeric Polypeptides
KR102143506B1 (en) *	2011-08-17	2020-08-12	글락소 그룹 리미티드	Modified proteins and peptides
EP2812432B1 (en)	2012-02-10	2020-10-14	Research Corporation Technologies, Inc.	Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2013163427A1 (en)	2012-04-25	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibodies to treat hiv-1 infection
RU2014149681A (en)	2012-05-24	2016-07-20	Ф. Хоффманн-Ля Рош Аг	MULTIPLE SPECIFICITY ANTIBODIES
RU2650868C2 (en) *	2012-07-13	2018-04-17	Займворкс Инк.	Bispecific asymmetric heterodimers comprising anti-cd3 constructs
US20150203591A1 (en)	2012-08-02	2015-07-23	Regeneron Pharmaceuticals, Inc.	Mutivalent antigen-binding proteins
US9915665B2 (en)	2012-12-28	2018-03-13	Abbvie Inc.	High-throughput system and method for identifying antibodies having specific antigen binding activities
DK2943511T3 (en)	2013-01-14	2019-10-21	Xencor Inc	NEW HETERODIMERIC PROTEINS
KR102561553B1 (en) *	2013-03-15	2023-07-31	젠코어 인코포레이티드	Heterodimeric proteins
US11384149B2 (en) *	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (en) *	2013-08-09	2018-03-26	Макродженікс, Інк.	SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EA035419B9 (en) *	2014-05-29	2020-08-07	Мэкроудженикс, Инк.	Tri-specific binding molecules and methods of use thereof
TWI693232B (en) *	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
SG11201702310QA (en) *	2014-09-26	2017-04-27	Macrogenics Inc	Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
AU2015323860B2 (en) *	2014-09-29	2021-05-27	Duke University	Bispecific molecules comprising an HIV-1 envelope targeting arm
AU2015380455A1 (en) *	2015-01-26	2017-08-03	Macrogenics, Inc.	Multivalent molecules comprising DR5-binding domains
CA2995709A1 (en) *	2015-08-17	2017-02-23	Macrogenics,Inc.	Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
AR106935A1 (en) *	2015-12-04	2018-03-07	Macrogenics Inc	MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN CD19 AND CD3, AND USES OF THE SAME
EP3448427A1 (en) *	2016-04-29	2019-03-06	CureVac AG	Rna encoding an antibody
RU2022101891A (en) *	2016-06-07	2022-02-07	Мэкроудженикс, Инк.	APPLICATIONS OF CD32B X CD79B BINDING MOLECULES IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS
SG11201907753TA (en) *	2017-02-24	2019-09-27	Macrogenics Inc	Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2019118266A1 (en) *	2017-12-12	2019-06-20	Macrogenics Inc.	Bispecific cd 16-binding molecules and their use in the treatment of disease
CA3089877A1 (en) *	2018-02-15	2019-08-22	Macrogenics, Inc.	Variant cd3-binding domains and their use in combination therapies for the treatment of disease
US20210246194A1 (en) *	2018-05-18	2021-08-12	Macrogenics, Inc.	Optimized gp41-Binding Molecules and Uses Thereof

2015
- 2015-09-22 SG SG11201702310QA patent/SG11201702310QA/en unknown
- 2015-09-22 EA EA201790719A patent/EA201790719A1/en unknown
- 2015-09-22 MD MDA20170040A patent/MD20170040A2/en not_active Application Discontinuation
- 2015-09-22 PE PE2017000512A patent/PE20170894A1/en not_active Application Discontinuation
- 2015-09-22 JP JP2017516489A patent/JP6839075B2/en active Active
- 2015-09-22 MX MX2017003784A patent/MX375669B/en active IP Right Grant
- 2015-09-22 US US15/514,334 patent/US10633443B2/en active Active
- 2015-09-22 UY UY0001036316A patent/UY36316A/en unknown
- 2015-09-22 MA MA040573A patent/MA40573A/en unknown
- 2015-09-22 CA CA2962603A patent/CA2962603A1/en active Pending
- 2015-09-22 CU CUP2017000041A patent/CU20170041A7/en unknown
- 2015-09-22 EP EP15844698.9A patent/EP3197917B1/en active Active
- 2015-09-22 CR CR20170109A patent/CR20170109A/en unknown
- 2015-09-22 ES ES15844698T patent/ES2935062T3/en active Active
- 2015-09-22 CN CN201580051198.9A patent/CN107484416A/en active Pending
- 2015-09-22 AU AU2015321546A patent/AU2015321546B2/en active Active
- 2015-09-22 KR KR1020177010716A patent/KR20170063755A/en not_active Ceased
- 2015-09-22 TN TN2017000106A patent/TN2017000106A1/en unknown
- 2015-09-22 TW TW104131330A patent/TWI706960B/en active
- 2015-09-22 WO PCT/US2015/051314 patent/WO2016048938A1/en active Application Filing
- 2015-09-22 AP AP2017009823A patent/AP2017009823A0/en unknown
- 2015-09-22 AR ARP150103050A patent/AR101997A1/en unknown
2017
- 2017-03-22 ZA ZA2017/01985A patent/ZA201701985B/en unknown
- 2017-03-23 PH PH12017500544A patent/PH12017500544A1/en unknown
- 2017-03-23 DO DO2017000083A patent/DOP2017000083A/en unknown
- 2017-03-24 CO CONC2017/0002793A patent/CO2017002793A2/en unknown
- 2017-03-24 CL CL2017000711A patent/CL2017000711A1/en unknown
- 2017-03-24 NI NI201700037A patent/NI201700037A/en unknown
- 2017-03-26 IL IL251377A patent/IL251377B/en active IP Right Grant
2020
- 2020-03-03 US US16/807,514 patent/US11639386B2/en active Active
2023
- 2023-03-20 US US18/186,353 patent/US20230399399A1/en active Pending

Also Published As

Publication number	Publication date
US10633443B2 (en)	2020-04-28
AP2017009823A0 (en)	2017-03-31
ZA201701985B (en)	2018-05-30
AU2015321546B2 (en)	2020-09-03
KR20170063755A (en)	2017-06-08
MX2017003784A (en)	2017-06-28
NZ730348A (en)	2024-03-22
IL251377B (en)	2021-03-25
NI201700037A (en)	2017-07-18
TW201617369A (en)	2016-05-16
TWI706960B (en)	2020-10-11
US20170247452A1 (en)	2017-08-31
PH12017500544A1 (en)	2017-08-07
WO2016048938A1 (en)	2016-03-31
ES2935062T3 (en)	2023-03-01
US20230399399A1 (en)	2023-12-14
EA201790719A1 (en)	2017-07-31
JP6839075B2 (en)	2021-03-03
JP2017533891A (en)	2017-11-16
CU20170041A7 (en)	2017-09-06
EP3197917A1 (en)	2017-08-02
IL251377A0 (en)	2017-05-29
CL2017000711A1 (en)	2017-12-15
UY36316A (en)	2016-04-29
CO2017002793A2 (en)	2017-06-20
CA2962603A1 (en)	2016-03-31
CR20170109A (en)	2017-07-26
MA40573A (en)	2016-03-31
US11639386B2 (en)	2023-05-02
AR101997A1 (en)	2017-01-25
MD20170040A2 (en)	2017-07-31
EP3197917B1 (en)	2022-10-12
EP3197917A4 (en)	2018-06-27
DOP2017000083A (en)	2017-04-30
MX375669B (en)	2025-03-06
TN2017000106A1 (en)	2018-07-04
PE20170894A1 (en)	2017-07-12
US20200216537A1 (en)	2020-07-09
BR112017005988A2 (en)	2017-12-19
AU2015321546A1 (en)	2017-04-13
CN107484416A (en)	2017-12-15

Publication	Publication Date	Title
IL251377B (en)	2021-03-25	Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
ZA202006983B (en)	2023-03-29	Bispecific antibody constructs binding dll3 and cd3
HK1249423A1 (en)	2018-11-02	Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
AP2016009029A0 (en)	2016-02-29	Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof
HRP20181802T1 (en)	2018-12-28	Human cd3 binding antibody
HK1248250A1 (en)	2018-10-12	Bispecific antibody constructs binding mesothelin and cd3
ZA201701341B (en)	2021-05-26	Bispecific her2 and cd3 binding molecules
IL244238B (en)	2019-12-31	Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
EP3094737A4 (en)	2017-08-09	Bi-specific cd3 and cd19 antigen-binding constructs
IL247590A0 (en)	2016-11-30	Bi-specific antibodies and uses thereof
TH1601000783A (en)	2017-08-31	Bi-specific monovalent diabodies capable of binding CD123 and CD3, and their uses
LT3035965T (en)	2021-04-12	Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof